Mazor Robotics Ltd. (TASE:MZOR) (NASDAQGM:MZOR), a developer of innovative guidance systems and complementary products, announced today its financial results for the first quarter ended March 31, 2015.
“During the first quarter we sold a Renaissance system in the U.S., Germany and Taiwan, increasing our install base to 86 systems, which represents a 26% increase compared to 68 systems at the end of the year-ago period,” commented Ori Hadomi, Mazor's Chief Executive Officer. “There were a record number of clinical procedures using the Renaissance system in the first quarter. We are encouraged with the continued growth in the number of spine and brain procedures which clearly demonstrates that surgeons and hospital administrators are realizing the clinical and economic benefits of the Renaissance system. We recently surpassed the 10,000th procedure performed globally with Renaissance. While this is a significant achievement, it represents a small fraction of the overall market opportunity. Our entire organization is focused on executing our sales strategy and accelerating Renaissance’s adoption as the standard of care.”
FIRST QUARTER 2015 FINANCIAL RESULTS ON IFRS BASIS ("GAAP")
Revenue for the three months ended March 31, 2015 was $4.5 million compared to $4.9 million in the year-ago first quarter. U.S. generated revenue decreased to $2.7 million compared to $3.6 million in the year-ago quarter, as the Company sold one Renaissance system in the U.S. market during the first quarter of 2015 compared to three systems sold in the 2014 first quarter. International revenue increased to $1.8 million from $1.3 million reported in the first quarter of 2014. The Company sold two Renaissance systems in the International market compared to two systems sold in the 2014 first quarter, demonstrating higher pricing due to a one-time direct sale in Taiwan. Revenue from system kit sales, services and other, increased to $2.7 million in the first quarter of 2015, representing a 35% increase compared to $2.0 million in the first quarter of 2014, mainly attributed to increased utilization of the Renaissance system.
Gross margin for three months ended March 31, 2015 was 75.7% compared to 78.9% in the year-ago quarter, due to lower system sales in the first quarter of 2015.
Total operating expenses were $8.5 million compared to $7.5 million in the first quarter of 2014, primarily reflecting the Company’s increased investments in sales and marketing activities including a commission of $0.3 million related to the one-time direct sale in Taiwan. Operating loss was $5.1 million compared to an operating loss of $3.6 million in the year-ago first quarter. Net loss for the first quarter of 2015 was $5.2 million, or $0.12 per share, compared to a net loss of $3.6 million, or $0.09 per share in the first quarter of 2014.
Cash used in operating activities was $4.2 million compared to $5.3 million used in last year’s first quarter. As of March 31, 2015, cash, cash equivalents and investments totaled $48 million.
FIRST QUARTER 2015 FINANCIAL RESULTS ON NON-GAAP BASIS
The tables below include a reconciliation of the Company’s GAAP results to non-GAAP results. The reconciliation primarily relates to non-cash expense in the amount of $0.8 million with respect to share-based payments in the first quarter of 2015. On a non-GAAP basis, the net loss in the first quarter of 2015 was $4.4 million, or $0.11 per share, compared to $3.2 million, or $0.08 per share, in the first quarter of 2014.
CONFERENCE CALL INFORMATION
The Company will host a
conference call to discuss these results on Thursday, May 7, 2015, at
8:30 AM EST (3:30 PM IST). Investors within the United States interested
in participating are invited to call 877-269-7756. Participants in
Israel can use the toll free dial-in number 809 406 247. All other
international participants can use the dial-in number 201-689-7817.
A replay of the event will be available for two weeks following the conclusion of the call. To access the replay, callers in the United States can call 877-660-6853 and reference the Replay Access Code: 13607664. All international callers can dial 201-612-7415, using the same Replay Access Code. To access the webcast, please visit www.mazorrobotics.com and select ‘Investor Relations.’
Use of Non-GAAP Measures
In addition to disclosing financial results calculated in accordance with generally accepted accounting principles in conformity with International Financial Reporting Standards (GAAP), this press release contains Non-GAAP financial measures for gross profit, operating expenses, operating loss, net loss and basic and diluted earnings per share that exclude the effects of non-cash expense of amortization of intangible assets and stock-based payments. Management believes that these non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performance that enhances management's and investors' ability to evaluate the Company's net income and earnings per share and to compare them to historical net income and earnings per share.
The presentation of this non-GAAP financial information is not intended to be considered in isolation or as a substitute for the financial information prepared and presented in accordance with GAAP. Management uses both GAAP and non-GAAP measures when operating and evaluating the Company’s business internally and therefore decided to make these non-GAAP adjustments available to investors.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and other securities laws. Any statements
in this release about future expectations, plans or prospects for the
Company, including without limitation, statements regarding the market
opportunity for the Renaissance system, the greater adoption of and the
expansion of the presence of Renaissance, the priorities that the
Company will focus on to assure its long term success, that the Company
believes it will experience growth in 2015 and beyond, and other
statements containing the words “believes,” “anticipates,” “plans,”
“expects,” “will” and similar expressions are forward-looking
statements. These statements are only predictions based on Mazor's
current expectations and projections about future events. There are
important factors that could cause Mazor's actual results, level of
activity, performance or achievements to differ materially from the
results, level of activity, performance or achievements expressed or
implied by the forward-looking statements. Those factors include, but
are not limited to, the impact of general economic conditions,
competitive products, product demand and market acceptance risks,
reliance on key strategic alliances, fluctuations in operating results,
and other factors indicated in Mazor's filings with the Securities and
Exchange Commission (SEC) including those discussed under the heading
"Risk Factors" in Mazor’s annual report on Form 20-F filed with the SEC
on April 29, 2015 and in subsequent filings with the SEC. For more
details, refer to Mazor's SEC filings. Mazor undertakes no obligation to
update forward-looking statements to reflect subsequent occurring events
or circumstances, or to changes in our expectations, except as may be
required by law.
Mazor Robotics Ltd.
CONSOLIDATED STATEMENT OF PROFIT OR
LOSS AND OTHER COMPREHENSIVE INCOME
(in thousands, except
per share data)
| Three month period | ||||||||
| ended March 31, | ||||||||
| 2015 (Unaudited) | 2014 (Unaudited) | |||||||
| Revenue | $ | 4,510 | $ | 4,878 | ||||
| Cost of revenue | $ | 1,097 | $ | 1,031 | ||||
| Gross profit | $ | 3,413 | $ | 3,847 | ||||
| Operating costs and expenses: | ||||||||
| Research and development | $ | 1,474 | $ | 1,644 | ||||
| Selling and Marketing | $ | 5,948 | $ | 4,911 | ||||
| General and administrative | $ | 1,103 | $ | 910 | ||||
| Total operating costs and expenses | $ | 8,525 | $ | 7,465 | ||||
| Loss from operations | $ | (5,112) | $ | (3,618) | ||||
| Financing income (expenses), net | $ | (61) | $ | 24 | ||||
| Loss before taxes on income | $ | (5,173) | $ | (3,594) | ||||
| Income tax expense | $ | 29 | $ | 40 | ||||
| Net loss | $ | (5,202) | $ | (3,634) | ||||
| Net loss per share – Basic and diluted | $ | (0.12) | $ | (0.09) | ||||
| Weighted average common shares outstanding – Basic and diluted | 42,172 | 41,120 | ||||||
Mazor Robotics Ltd.
CONSOLIDATED STATEMENTS OF FINANCIAL
POSITION AS OF
(U.S. Dollars in thousands)
| March 31, | December 31, | |||||||
| 2015 | 2014 | |||||||
| (Unaudited) | (Audited) | |||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 20,084 | $ | 22,255 | ||||
| Short-term investment | $ | 24,260 | $ | 24,507 | ||||
| Trade receivables | $ | 2,075 | $ | 2,797 | ||||
| Other current assets | $ | 1,330 | $ | 1,110 | ||||
| Inventory | $ | 3,147 | $ | 3,050 | ||||
| Total Current Assets | $ | 50,896 | $ | 53,719 | ||||
| Non-Current Assets | ||||||||
| Prepaid lease fee | $ | 77 | $ | 79 | ||||
| Deferred tax assets | $ | 129 | $ | 158 | ||||
| Property and equipment, net | $ | 1,176 | $ | 1,257 | ||||
| Long-term investments | $ | 3,722 | $ | 5,473 | ||||
| Total Non-Current Assets | $ | 5,104 | $ | 6,967 | ||||
| Total assets | $ | 56,000 | $ | 60,686 | ||||
| Current liabilities | ||||||||
| Trade payables | $ | 1,306 | $ | 1,689 | ||||
| Other current liabilities | $ | 4,415 | $ | 4,452 | ||||
| Total current liabilities | $ | 5,721 | $ | 6,141 | ||||
| Non-Current Liabilities | ||||||||
| Employee benefits | $ | 273 | $ | 278 | ||||
| Total Non-Current liabilities | $ | 273 | $ | 278 | ||||
| Total liabilities | $ | 5,994 | $ | 6,419 | ||||
| Equity | ||||||||
| Share capital | $ | 110 | $ | 110 | ||||
| Share premium | $ | 135,500 | $ | 135,182 | ||||
| Amounts allocated to share options | $ | 77 | $ | 77 | ||||
| Capital reserve for share-based payment transactions | $ | 5,209 | $ | 4,586 | ||||
| Foreign currency translation reserve | $ | 2,119 | $ | 2,119 | ||||
| Accumulated loss | $ | (93,009) | $ | (87,807) | ||||
| Total equity | $ | 50,006 | $ | 54,267 | ||||
| Total liabilities and equity | $ | 56,000 | $ | 60,686 | ||||
Mazor Robotics Ltd.
CONSOLIDATED CASH FLOW STATEMENTS
(U.S.
Dollars in thousands)
| Three month period | ||||||||
| ended March 31, | ||||||||
| 2015 (Unaudited) | 2014 (Unaudited) | |||||||
| Cash flows from operating activities: | ||||||||
| Loss for the period | $ | (5,202) | $ | (3,634) | ||||
| Adjustments: | ||||||||
| Depreciation and amortization | $ | 124 | $ | 161 | ||||
| Finance (income) expenses, net | $ | (32) | $ | 72 | ||||
| Share-based payment | $ | 758 | $ | 353 | ||||
| Income tax expense | $ | 29 | $ | 40 | ||||
| $ | 879 | $ | 626 | |||||
| Change in inventory | $ | (97) | $ | (234) | ||||
| Change in trade and other accounts receivable | $ | 615 | $ | (1,663) | ||||
| Change in prepaid lease fees | $ | 2 | $ | (5) | ||||
| Change in trade and other accounts payable | $ | (310) | $ | (446) | ||||
| Change in employee benefits | $ | (5) | $ | 25 | ||||
| $ | 205 | $ | (2,323) | |||||
| Interest received | $ | 12 | $ | 2 | ||||
| Income tax paid | $ | (108) | $ | (11) | ||||
| $ | (96) | $ | (9) | |||||
| Net cash used in operating activities | $ | (4,214) | $ | (5,340) | ||||
| Cash flows from investing activities: | ||||||||
| Proceeds from (investments in) short-term investments, net | $ | 1,998 | $ | (1,752) | ||||
| Purchase of property and equipment | $ | (43) | $ | (124) | ||||
| Net cash provided by (used in) investing activities | $ | 1,955 | $ | (1,876) | ||||
| Cash flows from financing activities: | ||||||||
| Issuance expenses | $ | - | $ | (294) | ||||
| Proceeds from exercise of share options by employees | $ | 183 | $ | 2,384 | ||||
| Repayment of loans to the Chief Scientist | $ | - | $ | (324) | ||||
| Net cash provided by financing activities | $ | 183 | $ | 1,766 | ||||
| Net decrease in cash and cash equivalents | $ | (2,076) | $ | (5,450) | ||||
| Cash and cash equivalents at the beginning of the period | $ | 22,255 | $ | 19,803 | ||||
| Effect of exchange rate differences on balances of | ||||||||
| cash and cash equivalents | $ | (95) | $ | (28) | ||||
| Cash and cash equivalents at the end of the period | $ | 20,084 | $ | 14,325 | ||||
Mazor Robotics Ltd.
RECONCILIATIONS OF GAAP TO NON-GAAP
FINANCIAL MEASURES
(U.S. Dollars in thousands, except per
share data)
(UNAUDITED)
| Three month period | ||||||||
| ended March 31, | ||||||||
| 2015 | 2014 | |||||||
| GAAP gross profit | $ | 3,413 | $ | 3,847 | ||||
| Amortization of intangible assets | $ | - | $ | 73 | ||||
| Share-based payments | $ | 36 | $ | 7 | ||||
| Non-GAAP gross profit | $ | 3,449 | $ | 3,927 | ||||
| GAAP gross profit as percentage of revenues | 75.7% | 78.9% | ||||||
| Non-GAAP gross profit as percentage of revenues | 76.5% | 80.5% | ||||||
| GAAP operating expenses | $ | 8,525 | $ | 7,465 | ||||
| Share-based payments: | ||||||||
| Research and development | $ | 124 | $ | 38 | ||||
| Selling and marketing | $ | 389 | $ | 200 | ||||
| General and administrative | $ | 209 | $ | 108 | ||||
| Non-GAAP operating expenses | $ | 7,803 | $ | 7,119 | ||||
| GAAP operating loss | $ | (5,112) | $ | (3,618) | ||||
| Non-GAAP operating loss | $ | (4,354) | $ | (3,192) | ||||
| GAAP net loss | $ | (5,202) | $ | (3,634) | ||||
| Share-based payments | $ | 758 | $ | 353 | ||||
| Amortization of intangible assets | $ | - | $ | 73 | ||||
| Non-GAAP net loss | $ | (4,444) | $ | (3,208) | ||||
| GAAP basic and diluted loss per share | $ | (0.12) | $ | (0.09) | ||||
| Non-GAAP basic and diluted loss per share | $ | (0.11) | $ | (0.08) | ||||
Contacts:
Investors
Michael
Polyviou/Doug Sherk, 212.850.6020; 415.652.9100
mpolyviou@evcgroup.com;
dsherk@evcgroup.com
or
Media
David
Schemelia, 646.201.5431
dave@evcgroup.com
